Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JCAR 015

Next Previous
Drug Profile

JCAR 015

Alternative Names: anti-CD19-CD28-zeta CAR transduced T cells - Juno Therapeutics; anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; CD28-modified CAR CD3+ T lymphocyte therapy - Juno Therapeutics; JCAR 15; JCAR015

Latest Information Update: 30 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Juno Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 31 May 2019 Efficacy and adverse events data from a phase I trial in Precursor B-cell lymphoblastic leukaemia lymphoma presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top